Niklas Czeloth

Dr. Niklas Czeloth is an Executive Director and Investment Manager at the Boehringer Ingelheim Venture Fund, based in Hesse, Germany. He transitioned into venture capital after building a strong foundation in the life sciences, earning an advanced diploma in biochemistry from the University of Hannover before completing his doctoral and postdoctoral research in immunology. In his current capacity, he specializes in the biotechnology and pharmaceutical sectors, directing institutional capital toward early-stage companies developing novel therapeutic approaches. As part of his active investment mandate, Czeloth serves as a board member at Refoxy Pharmaceuticals, where he recently participated in a €9.1 million financing round to advance their proprietary medical treatments. His professional career bridges rigorous academic science and institutional venture capital investing, maintaining a primary focus on translating complex immunological research into commercially viable healthcare solutions.